Fresenius Medical Care AG (FME.VI)
| Previous Close | 35.81 |
| Open | 35.68 |
| Bid | 35.82 x 0 |
| Ask | 36.26 x 0 |
| Day's Range | 35.68 - 36.35 |
| 52 Week Range | 31.16 - 49.43 |
| Volume | |
| Avg. Volume | 13 |
| Market Cap | 10.61B |
| Beta (5Y Monthly) | 0.86 |
| PE Ratio (TTM) | 21.84 |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | 1.19 (3.30%) |
| Ex-Dividend Date | May 17, 2024 |
| 1y Target Est | N/A |
- PR Newswire
Fresenius Medical Care takes next important step towards goal to reduce CO2 emissions in its operations
Fresenius Medical Care (FME), the world's leading provider of products and services for people with kidney disease, has signed five virtual power purchase agreements (vPPAs) with wind and solar energy project developers in Germany and the U.S. The projects are expected to feed around 580 gigawatt hours of renewable energy into the grid, which equals up to 46 percent of FME's most recently reported global consumption. The company is thus taking an important step towards its goal of reducing emiss
- PR Newswire
Moody's and S&P change Fresenius Medical Care's rating outlook to stable
Fresenius Medical Care (FME), the world's leading provider of products and services for individuals with renal diseases, today received from S&P Global, a leading rating agency, the change of its rating outlook to stable from negative (bbb-, stable outlook). Moody's changed the credit rating outlook from negative to stable on May 17 (baa3, stable outlook).
- PR Newswire
Fresenius Medical Care showcases leadership and innovation in kidney care disease at 61st European Renal Association (ERA) Congress 2024
Fresenius Medical Care (FME), the world's leading provider of products and services for individuals with renal diseases, today announced the presentation of nearly 40 company-affiliated research abstracts at the 61st European Renal Association (ERA) Congress, taking place May 23-26, 2024, in Stockholm, Sweden and virtually.
